BioCryst Pharmaceuticals | BCRX - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
BioCryst Pharmaceuticals USD 154.97M 16.62M 2026-06
Chugai Pharma JPY 426.6B 29.83B 2025-12
Daiichi Sankyo JPY 449.81B 92.35B 2026-03
DBV Technologies USD 174.9M 54.3M 2026-06
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Gilead Sciences USD 7.63B 64M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Glaxosmithkline GBP 3.44B 146M 2026-03
Incyte USD 3.98B 33.45M 2026-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
Karyopharm Therapeutics USD 90.85M 30.31M 2026-03
Neurocrine Biosciences USD 332.4M 65.9M 2026-06
Novavax USD 191.46M 36.9M 2026-06
PTC Therapeutics USD 1.05B 215.9M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06